Who are ILX651's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zanaflex, Moxonidin, Tenex, SODIUM IODIDE I 131, Reglan, Colace.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ilx651.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ILX651 — Competitive Intelligence Brief

ILX651 (ILX651) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NIS inhibitor. Area: Oncology.

phase 2 NIS inhibitor NIS Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ILX651 (ILX651) — Genzyme, a Sanofi Company. ILX651 is a small molecule inhibitor of the sodium-iodide symporter (NIS) with potential use in thyroid cancer treatment.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ILX651 TARGET	ILX651	Genzyme, a Sanofi Company	phase 2	NIS inhibitor	NIS
Zanaflex	TIZANIDINE	Legacy Pharma Usa	marketed	Central alpha-2 Adrenergic Agonist	Nischarin	1996-01-01
Moxonidin	MOXONIDINE		marketed	moxonidine	Nischarin	1991-01-01
Tenex	GUANFACINE	Promius Pharma	marketed	Central alpha-2 Adrenergic Agonist	Nischarin	1986-01-01
SODIUM IODIDE I 131	SODIUM IODIDE I 131		marketed		sodium-iodide symporter (NIS), thyroid peroxidase	1982-01-01
Reglan	Metoclopramide Hydrochloride	Hikma	marketed	Prokinetic agent	Acetylcholine receptor sensitization; dopamine antagonism (implied)	1979-01-01
Colace	docusate sodium	Generic (multiple manufacturers)	marketed	Stool softener (surfactant laxative)	N/A (surfactant mechanism)	1955-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-12-22 — Reglan · 11813231 · Formulation · US
2029-12-22 — Reglan · 12194009 · Method of Use · US
2029-12-22 — Reglan · 12194008 · Method of Use · US
2029-12-22 — Reglan · 11020361 · Method of Use · US
2029-12-22 — Reglan · 11628150 · Formulation · US
2030-05-16 — Reglan · 8334281 · Formulation · US
2038-11-17 — Reglan · 12377064 · Method of Use · US

Sponsor landscape (NIS inhibitor class)

Genzyme, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ILX651 — Competitive Intelligence Brief. https://druglandscape.com/ci/ilx651. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab